Login to Your Account

Are high drug prices the chicken or the egg for 340B growth?

By Mari Serebrov
Regulatory Editor

Thursday, October 12, 2017

While just an undercurrent in Wednesday's House subcommittee hearing on oversight of the 340B prescription drug discount program, high U.S. drug prices were cited as a factor in the growth of the program and, at the same time, explained as the downstream outcome of that growth.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription